Partnership Aims to Improve OncoPrism Predictive Diagnostic
Culmination Bio and Cofactor Genomics are partnering to leverage biobank samples and data to develop the OncoPrism test for 11 cancers.
Read MorePosted by Melanie Hamilton-Basich | Jun 15, 2023 | Cancer |
Culmination Bio and Cofactor Genomics are partnering to leverage biobank samples and data to develop the OncoPrism test for 11 cancers.
Read MorePosted by Melanie Hamilton-Basich | Jun 14, 2023 | Colorectal |
If given a way to get home from a colonoscopy after sedation, many patients will seek out a procedure they would otherwise avoid.
Read MorePosted by Melanie Hamilton-Basich | Jun 13, 2023 | Cancer, Molecular Diagnostics |
Pfizer and Thermo Fisher Scientific Inc. have entered into a collaboration agreement to help increase local access to next-generation sequencing-based testing for lung and breast cancer patients.
Read MorePosted by Melanie Hamilton-Basich | Jun 7, 2023 | Cancer |
The analysis showed strong performance of Grail’s MCED methylation-based platform in the symptomatic population of more than 6,000 patients
Read MorePosted by Melanie Hamilton-Basich | Jun 6, 2023 | Cancer, Sequencing Systems |
The study’s multi-cancer early detection data show Exai’s RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
Read More